C C Miller 3rd
Overview
Explore the profile of C C Miller 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miller 3rd C, Villa M, Sutton J, Lau D, Keyhani K, Estrera A, et al.
Eur J Vasc Endovasc Surg
. 2009 Feb;
37(4):388-94.
PMID: 19232502
Objectives: The intractability of renal dysfunction following thoracic and thoraco-abdominal aortic repair leads us to believe that the accepted mechanisms of renal injury - ischaemia and embolism - are incompletely...
2.
Bowen R, Foreyt J, Poston 2nd W, Miller 3rd C, Hyman D, Pendleton V, et al.
Endocr Pract
. 2004 Jul;
5(1):17-23.
PMID: 15251698
Objective: To describe the prevalence and evaluate the risk of echocardiogram-determined valvulopathy in patients who received fenfluramine and phentermine in an effort to lose weight, in comparison with normal control...
3.
Miller 3rd C, Porat E, Estrera A, Vinnerkvist A, Huynh T, Safi H
Eur J Vasc Endovasc Surg
. 2004 Jul;
28(2):154-7.
PMID: 15234696
Background: Number needed to treat (NNT) is a method used to calculate the number of patients who need to be treated to prevent one adverse outcome. To analyze the effectiveness...
4.
Huynh T, Miller 3rd C, Estrera A, Sheinbaum R, Allen S, Safi H
J Vasc Surg
. 2002 Apr;
35(4):648-53.
PMID: 11932657
Purpose: Extended hospital length of stay (LOS) and consequent high costs are associated with thoracic and thoracoabdominal aortic aneurysm (TAAA) surgery. In this study, we examined factors that may influence...
5.
Safi H, Miller 3rd C, Estrera A, Huynh T, Porat E, Hassoun H, et al.
Eur J Vasc Endovasc Surg
. 2002 Mar;
23(3):244-50.
PMID: 11914012
Objective: chronic aortic dissection has long been considered a risk factor for neurologic deficit following thoracoabdominal aortic aneurysm (TAA) surgery. We reviewed our experience with regard to aneurysm extent and...
6.
Staged repair of extensive aortic aneurysms: morbidity and mortality in the elephant trunk technique
Safi H, Miller 3rd C, Estrera A, Huynh T, Rubenstein F, Subramaniam M, et al.
Circulation
. 2001 Dec;
104(24):2938-42.
PMID: 11739309
Background: Extensive aortic aneurysms (ascending aorta, aortic arch, and descending or thoracoabdominal aorta) require innovative surgical techniques. Some surgeons advocate a single procedure with long periods of profound hypothermia, whereas...
7.
Letsou G, HOGAN J, Bsee , Miller 3rd C, Elefteriades J, Francischelli D, et al.
Ann Thorac Surg
. 2001 Oct;
72(4):1336-42; discussion 1343.
PMID: 11603457
Background: Optimal clinical stimulation for skeletal muscle cardiac assist systems (such as dynamic cardiomyoplasty) is not clearly defined. The pressure-generating capacity of canine skeletal muscle ventricles (SMVs) at a variety...
8.
Estrera A, Miller 3rd C, Huynh T, Porat E, Safi H
Ann Thorac Surg
. 2001 Oct;
72(4):1225-30; discussion 1230-1.
PMID: 11603441
Background: Neurologic deficit (paraparesis and paraplegia) after repair of the thoracic and thoracoabdominal aorta remains a devastating complication. The purpose of this study was to determine the effect of cerebrospinal...
9.
Estrera A, Rubenstein F, Miller 3rd C, Huynh T, Letsou G, Safi H
Ann Thorac Surg
. 2001 Aug;
72(2):481-6.
PMID: 11515886
Background: Neurologic deficit (paraplegia or paraparesis) remains a significant morbidity in the repair of descending thoracic aortic aneurysm. Methods: Between February 1991 and February 2000, we operated on 182 patients...
10.
Dolan J, Miltenburg D, Granchi T, Miller 3rd C, Brunicardi F
Ann Surg Oncol
. 2001 Apr;
8(3):227-33.
PMID: 11314939
Background: Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues,...